NURO Share Price

Open 1.08 Change Price %
High 1.08 1 Day -0.02 -1.90
Low 0.97 1 Week 0.13 14.44
Close 1.03 1 Month -0.10 -8.85
Volume 179286 1 Year -1.58 -60.54
52 Week High 2.96
52 Week Low 0.88
NURO Important Levels
Resistance 2 1.13
Resistance 1 1.09
Pivot 1.03
Support 1 0.97
Support 2 0.93
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

NeuroMetrix, Inc. (NASDAQ: NURO)

NURO Technical Analysis 5
As on 9th Dec 2016 NURO Share Price closed @ 1.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.57 & Strong Sell for SHORT-TERM with Stoploss of 1.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
NURO Target for December
1st Target up-side 1.17
2nd Target up-side 1.35
3rd Target up-side 1.54
1st Target down-side 0.65
2nd Target down-side 0.47
3rd Target down-side 0.28
NURO Other Details
Segment EQ
Market Capital 6412515.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.neurometrix.com
NURO Address
NURO
62 Fourth Avenue
Waltham, MA 02451
United States
Phone: 781-890-9989
Interactive Technical Analysis Chart NeuroMetrix, Inc. ( NURO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on NeuroMetrix, Inc.
NURO Business Profile
NeuroMetrix, Inc. (NeuroMetrix) is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company is in the position to address these unmet needs through the development of medical devices. The Company intends to advance its objectives in the diabetic neuropathy market include: Driving Commercial Adoption of Products for Diabetic Neuropathy in the United States. The Company develops and market neurodiagnostic systems, which typically consists of a medical device plus single patient-use biosensors or electrodes.The Company�s NC-stat DPNCheck consists of an electronic hand-held device and a single patient use biosensor. More than 1.7 million patient studies have been performed using the Company's NC-stat technology and there have been approximately 6.3 million nerve tests, including nearly 700,000 sural nerve tests.